BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Peretinoin: Phase II/III data

In a double-blind, Japanese Phase II/III trial in 401 HCV-positive HCC patients who underwent curative therapy with surgical resection or transcutaneous radiofrequency ablation, 600 mg/day oral peretinoin for up to 96 weeks met the primary...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >